Australia's Argent BioPharma rises on $5.5 million global licensing deal

Argent BioPharma

07/07/2026 04:41

** Shares of Argent BioPharma RGT.AX rise 148.6% to A$0.087, their highest level since November 10
** Company executes global licensing transaction for CannEpil with $5.5 million upfront consideration
** CannEpil is company's neurological asset developed for the management of drug-resistant epilepsy.
** About 13.8 million shares change hands, 278.6x the 30-day average of 49,686
** Stock up 18.6%, YTD

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)
 ((Jasmeenaraislam.Shaikh@thomsonreuters.com;))